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The management of atherosclerotic carotid occlusive disease for stroke prevention has entered a time of dramatic change.
Improvements in medical management have begun to challenge traditional interventional approaches to asymptomatic carotid
stenosis. Simultaneously, carotid artery stenting (CAS) has emerged as an alternative to carotid endarterectomy (CE). Finally,
multiple factors beyond degree of stenosis and symptom status now mitigate clinical decision making. These factors include
brain perfusion, plaque morphology, and patency of intracranial collaterals (circle of Willis). With all of these changes, it seems
prudent to review the role of carotid duplex ultrasonography in the management of atherosclerotic carotid occlusive disease for
stroke prevention. Carotid duplex ultrasonography (CDU) for initial and serial imaging of the carotid bifurcation remains an
essential component in the management of carotid bifurcation disease. However, correlative axial imaging modalities (computer
tomographic angiography (CTA) and contrast-enhanced magnetic resonance angiography (CE-MRA)) increasingly aid in the
assessment of individual stroke risk and are important in treatment decisions. The purpose of this paper is twofold: (1) to discuss
foundations and advances in CDU and (2) to evaluate the current role of CDU, in light of other imaging modalities, in the clinical
management of carotid atherosclerosis.
1.Introduction
Carotid atherosclerosis is one of several etiological factors
for stroke, an important health problem with a high burden
of disease in the western world and in developing countries.
Of all strokes, an estimated 88% are ischemic in nature [1–
5]. Less than 20% of these are caused by atheroma in the
carotid bifurcation [6–8]. While the percentage of strokes
attributedtocarotiddiseaseisrelativelylow,theoverallsocial
and economic burden is high. It is, therefore, important to
identify and manage carotid atherosclerosis with the aim of
stroke prevention.
The mortality rate for stroke in the United States
has declined by nearly 70% since 1950 [9]. In Decem-
ber 2010, the Center for Disease Control and Prevention
announced stroke was the fourth leading cause of death
in the United States (down from its third place ranking
w h i c hi th e l df o rd e c a d e s )[ 10]. The identiﬁcation of major
risk factors through population-based studies [1, 11, 12]
and randomized controlled trials (RCTs) of symptomatic
[13–15] and asymptomatic [16, 17] patients has led to
eﬀective public health and clinic-based control strategies.
These strategies include combining community education
and targeted medical and surgical intervention in patients
with increased stroke risk and have contributed, in part, to
the fall in stroke mortality rates.
Diagnostic imaging has also played a central role in the
clinical management of patients with carotid atherosclerosis.
With the advent of vascular ultrasound in the 1980s, it
became possible to identify atheroma in the carotid bifur-
cation noninvasively. Compared to conventional catheter-
based angiography, CDU is a low-cost, low-risk, and highly2 International Journal of Vascular Medicine
portable alternative. As such, it is an attractive imaging
modality for asymptomatic as well as symptomatic patients.
The technique for CDU has evolved over the years as
has our understanding of the disease process. Traditionally,
patients were selected for intervention based on their clinical
presentation and the degree of luminal narrowing in the
internal carotid artery. Modern management includes an
individualized assessment of risk and takes into account
brain perfusion, plaque morphology, and the presence of
intracranial collateralization. These factors are essential in
risk stratiﬁcation and illustrate the importance of adding
correlative axial imaging studies to the diagnostic work-up.
2.Development ofCDUas aTechnique
CDU is useful and accurate in the assessment of the entire
spectrumof carotid atherosclerosis,frompreclinical intimal-
medial thickening to total internal carotid occlusion. The
modality easily detects minimal disease that is not hemo-
dynamically signiﬁcant. Overestimation of mild to moderate
degrees of stenoses, in fact, has been a consistent problem
[18]. Nevertheless, any test intended for screening must have
ahighdegreeofsensitivitytobeusedintheinitialassessment
of disease.
Hemodynamically signiﬁcant stenosis is diagnosed pri-
marily through the measurement of markedly elevated ﬂow
velocities using spectral Doppler, one component of CDU, in
the narrowed portion of the internal carotid lumen. The
increase in velocity is proportional to the severity of the
obstruction.Todiagnosestenosis,measurementsofpeaksys-
tolic velocity (PSV) are compared to velocity thresholds
derived from correlations with conventional angiography.
Secondary parameters for quantifying stenosis include end-
diastolic velocity, internal carotid artery (ICA) to common
carotid artery (CCA) ratio, degree of spectral broadening,
and presence of plaque on B-mode imaging. Other factors to
consider when interpreting studies include the presence of
calciﬁc plaque (with acoustical shadowing that may limit
visualization), contralateral high-grade stenosis, and kinking
or bends in the vessel (which may falsely elevate velocities).
The initial work into establishing clinically relevant
thresholds was done by investigators at the University of
Washington. They developed broad categories of stenosis
(Table 1) as follows: 1–15%, 16–49%, 50–79%, 80–99%, and
occluded [19]. These original criteria laid the foundation for
CDU interpretation of carotid artery stenosis. In 2003, the
criteria were modiﬁed following the results of several clinical
trials involving patients typically referred for CDU [20].
The Asymptomatic Carotid Atherosclerosis Study
(ACAS) was a landmark prospective, randomized clinical
trial which examined the role of carotid endarterectomy in
patients without symptoms (but with clinical markers for
atherosclerosis). ACAS randomized 1662 asymptomatic
patients with a 60% or greater ICA stenosis to either medical
therapy alone or to medical therapy plus CE. In 1995, this
study reported CE drastically reduced the estimated risk of
ipsilateral stroke or death from 11% to 5.1% [16]. Symp-
tomatic patients (presenting with a neurologic event such as
Table 1: University of Washington criteria [19].
University of Washington (Strandness)
Stenosis
(%)a
PSVb
(cm/s)
EDVc
(cm/s) Flow characteristics
1–15 <125 <140 No spectral broadening
16–49 <125 <140 Minimal spectral
broadening
50–79 ≥125 <140 Marked spectral
broadening
80–99 ≥125 >140 Marked spectral
broadening
Occlusion N/A N/A No internal carotid
ﬂow signal
aBased on conventional angiography using least transverse diameter at the
stenosis compared to the diameter of the distal uninvolved ICA where the
arterial walls become parallel, bpeak systolic velocity, cend diastolic velocity.
Table 2: Carotid Consensus Panel criteria [20].
Carotid Consensus Panel criteria (2003)
Stenosis
(%)a
PSVb
(cm/s)
EDVc
(cm/s) ICA/CCA ratio
Normal (no plaque) <125 <40 <2.0
<50 (plaque seen) <125 <40 <2.0
50–69 125–230 40–100 2.0–4.0
≥70 ≥230 >100 >4.0
aBased on conventional angiography using least transverse diameter at the
stenosis compared to the diameter of the distal uninvolved ICA where the
arterial walls become parallel, bpeak systolic velocity, cend diastolic velocity.
atransientischemicattack(TIA),stroke,oramaurosisfugax)
formed the basis for such well-known studies as the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) [13] and the European Carotid Surgery Trial
(ECST) [14]. Both trials reported a clear surgical beneﬁt in
patients with ≥70% stenosis. As a result of the RCTs, it was
determined that the utility of CDU could be increased by
redeﬁning thresholds to identify patients (asymptomatic or
symptomatic) with ≥60–99% stenosis. Thus, the criteria for
carotid artery stenosis were modiﬁed (Table 2) by a panel of
experts to be compatible with what were then accepted indi-
cations for CE, based on trial results [20].
AbuRahma et al. [24] used the criteria proposed by the
consensuspaneltoanalyzethecorrelationbetweenCDUand
angiography in 376 internal carotid arteries at their insti-
tution. They demonstrated a sensitivity of 93%, speciﬁcity
of 68%, and overall accuracy of 85% for carotid stenosis
between 50 and 69%. Using a cutoﬀ PSV of ≥230cm/s for
≥70% stenosis, they demonstrated a sensitivity of 99%,
speciﬁcity of 86%, and overall accuracy of 95%. Individual
vascular laboratories may have varying degrees of sensitivity
and speciﬁcity based on diﬀerent threshold criteria that have
been internally validated. Internal validation of Doppler
thresholds is recommended, but this may be diﬃcult given
the infrequency of correlative angiograms at most institu-
tions [20]. In the absence of internal validation, the consen-
sus panel criteria should be used for CDU interpretation.International Journal of Vascular Medicine 3
The technique of CDU continues to evolve as a result
of experience and advances in technology. Experience has
been gained through research, continuing education, and
establishment of quality standards through vascular lab
accreditation and credentialing of sonographers and inter-
preting physicians. Advances in technology include contin-
ued improvements in gray-scale resolution, Power Doppler,
and computer-assisted normalization of images to aid in
the evaluation of plaque surface and structure characteristics
[18]. No longer just a diagnostic tool, CDU guides inter-
vention in modern practice and plays an integral role in the
management of patients with carotid atherosclerosis.
3. ClinicalManagement of
Carotid Atherosclerosis
For nearly half a century, the management of carotid
atherosclerosis has been dictated by the severity of disease
(percent stenosis) and classiﬁcation of clinical presentation
between “symptomatic” and “asymptomatic”. The design
and results of previous clinical trials on surgical versus medi-
cal treatment of carotid atherosclerosis for stroke prevention
as well as current studies comparing CE and CAS have led
to this distinction. Currently, an individual’s risk of stroke
can be assessed by taking into account supplementary diag-
nostic information such as plaque morphology and the
integrity of intracranial collateralization. This information
identiﬁes plaque vulnerable to disruption and atheroembol-
ization leading to a better calculation of an individual’s
risk for stroke. The recognition of vulnerable plaque is also
paramount in the surgical management of carotid athe-
rosclerosis, particularly when CAS is planned.
Carotid plaques with a large lipid core and thin ﬁbrous
cap are more likely to rupture [31]. When the area of
plaque occupied by lipid components (macrophages and
extracellular lipids) is >40% of the area occupied by ﬁbro-
muscular components (smooth muscle cells and collagen),
the plaque is considered unstable [32]. A thin ﬁbrous cap is
the result of increased collagen degradation and decreased
collagen formation and is more susceptible to disruptive
hemodynamic forces [33].
Large pressure gradients across a stenosis can inﬂuence
plaque by increasing the wall shear stress (WSS) and causing
cap disruption [34, 35]. Li et al. have reported that WSS
rises with increasing severity of stenosis [34] .T h ed e g r e eo f
luminal narrowing, however, is just one factor contributing
to large pressure drops. Lal [36] recently studied the eﬀect
of incomplete intracranial collateralization on carotid ﬂow
rates and velocities and found the pressure drop across a
similar stenosis was signiﬁcantly higher for an incomplete
circle of Willis (CoW) compared with an intact CoW. In
their model, a carotid stenosis of 67%, when associated with
an incomplete CoW, contributed to markedly elevated WSS,
well beyond the threshold predictive of plaque rupture.
The identiﬁcation of additional parameters contributing
to an individual’s risk of stroke may warrant modiﬁcations
to the diagnostic work-up for carotid atherosclerosis. The
current role of CDU and correlative axial imaging (CE-MRA
and CTA) is outlined in Table 3 and discussed further in the
next section.
3.1. Current Role of CDU. The sensitivity and accuracy
of CDU in the detection of hemodynamically signiﬁcant
stenosis has led to its widespread use in the initial evaluation
of patients with neck bruits (and clinical risk factors
for atherosclerosis) and in symptomatic patients for the
detection of ≥70% carotid artery stenosis. But, the relative
low speciﬁcity of CDU, especially in the 50–69% category
(Table 3), justiﬁes the use of additional imaging for positive
selection of patients prior to undertaking any interventions.
This is of particular relevance in the clinical management of
asymptomatic patients with ≥60% stenosis, since as many
as 89% of these individuals remain stroke-free with medical
therapy alone [16].
While conventional angiography is still considered the
“gold standard” for deﬁning carotid disease, there has been
a growing interest in performing CE based on clinical
evaluation and CDU alone. One reason for this strategy is
to improve patient outcomes. There is a higher risk of stroke
(10–20%)withintheﬁrst14daysfollowingacerebrovascular
event. After this time, the stroke risk declines to that of
the “asymptomatic” stenosis (1-2%/year) [37]. To maximize
the beneﬁt of either CE or CAS, rapid assessment and early
interventionareneeded.CDUisreadilyaccessibleandallows
the fastest time to identify patients in need of invasive
therapy.
This trend has also been stimulated by improvements
in the accuracy and utility of CDU, along with increasing
demands to minimize both the risks and cost of medical
care. In many centers, carotid angiography is no longer done
routinely, even when planning intervention, to eliminate the
procedural risk of neurologic events, which is around 1%
[38, 39]. A survey of panelists convened for the Consensus
Criteria conference found as many as 80% of patients in
the United States undergo CE after a CDU as the only
preoperative imaging study [20]. Given the speciﬁcity of
68–86% [24] in CDU detection of stenosis above the
60% threshold, the practice of undertaking CE without
additional imaging suggests that unnecessary procedures
will be performed. When CE appears indicated by CDU,
conﬁrmatory imaging with CE-MRA should be considered.
If there is discordance between the two imaging modalities,
then CTA would be a suitable arbiter. It should be noted
that multiple imaging modalities may unfavorably delay
treatment when imaging resources are limited.
With the emergence of CAS as an alternative to CE, there
has been an increased focus on CDU’s ability to distinguish
plaque morphology. Plaque morphology includes surface
(smooth versus irregular) and structure (homogeneous, het-
erogeneous, hemorrhagic, calciﬁed, echolucent) character-
istics (Figure 1). Certain plaque characteristics can aﬀect
patient outcomes. For example, echolucency within a carotid
plaque correlates with the presence of lipid components and
is associated with increased neurologic events [38–40]a sa r e
plaques that are heterogeneous and/or irregular as opposed
to smooth and homogeneous [41]. This is a notable concern
in CAS since plaque is not removed but rather pushed to4 International Journal of Vascular Medicine
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(a) Hemorrhagic plaque (dark lipid core, white arrow) (b) Calciﬁc plaque (acoustical shadowing, white arrow)
(c) Irregular surface (heterogenous) (d) Smooth surface (homogeneous)
Figure 1: CDU and plaque morphology (structure and surface characteristics).
the side. The Imaging in Carotid Angioplasty and Risk of
Stroke (ICAROS) study conﬁrmed the relationship between
echolucent plaques and the risk of stroke during CAS, as
well as CDU’s ability to distinguish such plaques, through a
multicenter registry [42].
Individual risk assessment of patients being considered
for surgical intervention is limited with CDU. For example,
the assessment of plaque morphology is not routinely
available in every vascular lab and requires speciﬁc protocols
to assure standardization of results. The use of image
normalization and software calculation of gray-scale median
values can minimize inter- and intraobserver variability,
but is not the current standard of practice. CDU also fails
to provide diagnostic information with regard to brain
perfusion, arch pathology, intracranial collateralization, and
vascular anomalies such as aneurysms. The CoW can be
interrogated with transcranial Doppler, although few labs
employ this technique.
3.2. Surveillance with CDU following CAS and CE. Recurrent
stenosis is one of the most prevalent complications of CAS.
The current risk of hemodynamically signiﬁcant (≥80%)
in-stent restenosis (ISR) is 6.4% at 5 years [38]. Because
of the possibility of ISR and the importance of late stroke
prevention following CAS, strict follow-up and surveillance
with CDU are necessary. The same technique used in
preoperative assessment is applied. However, it is important
to note that previously published velocity criteria for CDU
were based on native, nonstented arteries. Blood ﬂow and
vessel compliance are altered in stented arteries, and the use
of existing criteria may overestimate the degree of restenosis
[28, 39–43]. Modiﬁed velocity criteria thresholds proposed
byLaletal.[29]andAbuRahmaetal.[28](T able4)c orr elat e
with clinically signiﬁcant ISR following CAS and should be
used for CDU surveillance in these patients.
ISR is primarily caused by neointimal hyperplasia. The
course of neointimal hyperplasia is diﬃcult to predict; it may
progress to a high-grade stenosis requiring reintervention or
Table 4: Comparison of modiﬁed criteria for ISR after CAS.
Modiﬁed criteria for ISR after CAS
Stenosis (%)a PSVb (cm/s) ICA/CCA ratio
Lal et al. (2008) [29]
0–19 <150 <2.15
20–49 150–219
50–79 220–339 ≥2.7
80–99 >340 ≥4.15
AbuRahma et al. (2008) [28]
0–29 <154 <1.5
30–49 154–223
50–79 224–324 ≥3.4
80–99 >325 ≥4.5
aBased on conventional angiography using least transverse diameter at the
stenosis compared to the diameter of the distal uninvolved ICA where the
arterial walls become parallel, bpeak systolic velocity.
follow a more benign course. Lal et al. [44] have studied
patterns of ISR and developed a classiﬁcation scheme based
on the length of the lesion and its relationship to the
stent which is predictive of the need for future remedial
intervention. Lesions >10mm long with extension beyond
the stent(s) margins were most worrisome and required
remedial intervention by transcatheter techniques in 58.8%
of their cases.
A full discussion of ISR is beyond the scope of this paper.
What is important is that CDU is a reproducible technique
that can be applied to the identiﬁcation and classiﬁcation of
types and severity of ISR. CDU surveillance should include
a thorough investigation of the stented segment noting
the length of any narrowing and its relationship to the
stent. Standard practice is to obtain baseline CDU prior to
discharge following CAS. Follow-up CDUs are obtained at
3 months and then at 6-month intervals for the next 18International Journal of Vascular Medicine 7
months. If there is no evidence of signiﬁcant ISR at two
years, surveillance CDUs are then performed annually [45].
Since long-term outcomes are still not well deﬁned, lifelong
s u r v e i l l a n c ew i t hC D Ui sr e c o m m e n d e d .
CDU surveillance following CE, on the other hand, is
a topic of controversy. Stroke prevention is the goal of any
surveillance program. Strokes can be prevented by detection
of signiﬁcant restenosis prior to the onset of neurologic
events and through follow-up of contralateral carotid bifur-
cation disease. Opponents to routine surveillance argue that
there is no real stroke prevention beneﬁt. While recurrent
stenosis is somewhat common after CE with a reported
incidence of 1% to 37%, fewer than 8% of patients become
symptomatic [46–48]. Restenosis rates are also aﬀected by
the type of closure (primary versus patch angioplasty) with
lower rates favored in the patch angioplasty group [49]. The
clinicalsigniﬁcanceofcarotidrestenosisfollowingCEhasled
someinvestigatorstoconcludethatpostoperativeCDUisnot
warranted. Current recommendations for CDU surveillance
following CE with primary closure are 1 month, 6 months,
and yearly [8]. For CE with patch closure, if CDU is normal
at 6 months (and there is no contralateral disease), routine
follow-up may not be necessary [50].
3.3. Routine CDU Screening for Asymptomatic Carotid Athe-
rosclerosis. Routine screening of the general asymptomatic
population is controversial. The United States Preventive
Services Task Force (USPSTF) recommended against routine
screeningforasymptomaticcarotidarterystenosisin2007.It
concluded it was not possible to identify people from a high-
riskgroup(withaprevalenceof5%) whomightbeneﬁtfrom
screening and treatment with CE or CAS [51].
Similarly, new guidelines on the management of patients
with carotid artery disease were released in January 2011 by
the American College of Cardiology Foundation/American
HeartAssociationTaskForceonPracticeGuidelines.Speciﬁc
to screening, the task force recommended against screening
in asymptomatic patients without signiﬁcant risk factors
for atherosclerosis or physical signs of carotid disease.
However, screening for carotid stenosis “may be considered
among individuals with at least two major risk factors for
atherosclerosis or with a diagnosis of other cardiovascular
disease such as coronary artery disease or peripheral artery
disease” [8].
Screening in high-risk groups has also been reported
in Hong Kong. Cheng et al. [52] used CDU to screen for
a s y m p t o m a t i cc a r o t i da r t e r ys t e n o s i si nag r o u po fe l d e r l y
(mean age 70.6 years) Chinese patients with known lower
extremity arterial disease. The prevalence of severe (≥70%)
internal carotid artery stenosis in this group was 24.7%. Age,
smoking quantity, and a carotid bruit were independent risk
factors associated with severe carotid disease. The degree of
carotid stenosis also correlated with age and the number and
duration of cigarette smoking. This study suggests it may be
possibletoidentifyagroupofpatientswithahighprevalence
of carotid stenosis that might beneﬁt from screening and
treatment with CE or CAS.
Vessel
Left
Mid
CCA
Current frame
IMT = 0.67 mm
Success = 100%
Width = 10 mm
Figure 2: Carotid IMT. Automated edge detection software used
to measure CIMT in the mid-common carotid artery (CCA). The
CIMT was calculated at 0.67mm in this patient.
4.EmergingAdvancesinCDU
Atherosclerosis is a systemic disease with potentially devas-
tating consequences such as stroke, ischemic heart disease,
and peripheral arterial disease. Emerging advances in carotid
ultrasound allow for the detection of atherosclerosis at its
earliest stages. These advances include the use of carotid
intima-media thickness (CIMT) calculations and adminis-
tration of contrast ultrasound agents during CDU.
The application of CIMT has become an accepted, reli-
able surrogate marker for determination of atherosclerosis
and is endorsed by the U.S. Food and Drug Administration
(FDA) and the European Agency for the Evaluation of
Medicinal Products [53, 54]. CIMT measurements correlate
well with histology, and increased IMT (Figure 2) is asso-
ciated with cardiovascular risk factors and the presence of
more advanced atherosclerosis. CIMT has led to improved
cardiovascular risk stratiﬁcation. Nambi et al. [53] used the
Atherosclerosis Risk in Communities (ARIC) database to
correlatecardiovasculareventstoCIMT.Intheintermediate-
risk group, 21.7% of participants were correctly reclassiﬁed
following the addition of CIMT to traditional risk factors.
This is an improvement to the widely accepted Framingham
Risk Score.
Contrast-enhanced ultrasound (CEUS) is another
emerging advancement in technology. While not routinely
used, contrast agents are an exciting adjunct to CDU and
have two potential beneﬁts. First, they can be used to
identify neovascularization within the adventitial layer of
the CCA which precedes the development of increased
IMT [25, 55]. Clinical application includes management of
atherosclerosis at its earliest stage of development. Second,
CEUS can be used to quantify plaque morphology by
identifying intraplaque neovascularization [56]. There is a
direct correlation between intraplaque neovascularization
and cardiovascular events (myocardial infarction, TIA,
stroke) [25, 55–57]. Consequently, CEUS has an emerging
role in the selection of patients for carotid intervention.
Despite the abundance of the literature on the beneﬁt
of advanced noninvasive technologies in the assessment of
cardiovascular risk, their role is still emerging. In the United
States, CIMT and CEUS are not generally reimbursable.
Additionally, contrast ultrasound agents are currently FDA8 International Journal of Vascular Medicine
approved only for use in the imaging of cardiac struc-
tures. Their oﬀ-label use in vascular imaging may require
institutional approval. In developing countries, emerging
advances in CDU may be of greater immediate beneﬁt. This
is especially true of CIMT which can be measured relatively
simply and is well-suited for large-scale population studies.
5. Conclusion
The role of CDU in the management of carotid atherosclero-
sis has evolved. The technique was developed as a diagnostic
tool to identify asymptomatic and symptomatic patients
with signiﬁcant (≥60–99%) carotid stenosis. These were the
patientslikelytobeneﬁtfromcarotidrevascularizationeither
by CE or CAS. Today, correlative axial imaging (CE-MRA
and CTA) studies supplement CDU and provide diagnostic
information on brain perfusion, plaque morphology, and
intracranial collateralization. These factors are important in
the individual assessment of stroke risk and may improve the
clinicalmanagementofpatientswithcarotidatherosclerosis.
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